Humana Inc. (NYSE:HUM) Shares Acquired by V Square Quantitative Management LLC

V Square Quantitative Management LLC increased its position in Humana Inc. (NYSE:HUM) by 3.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,620 shares of the insurance provider’s stock after purchasing an additional 96 shares during the period. V Square Quantitative Management LLC’s holdings in Humana were worth $665,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Creative Financial Designs Inc. ADV boosted its stake in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 61 shares during the period. Ashton Thomas Securities LLC acquired a new position in Humana in the third quarter valued at approximately $31,000. Your Advocates Ltd. LLP boosted its stake in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the period. Atwood & Palmer Inc. boosted its stake in Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 60 shares during the period. Finally, LRI Investments LLC boosted its stake in Humana by 1,021.4% in the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after acquiring an additional 143 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Trading Up 0.3 %

NYSE HUM opened at $253.61 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $30.54 billion, a PE ratio of 22.46, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The firm’s fifty day simple moving average is $271.83 and its 200-day simple moving average is $295.17.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, sell-side analysts anticipate that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. TD Cowen lifted their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Truist Financial boosted their price objective on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price objective on shares of Humana in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday. Finally, Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $293.05.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.